Atara receives FDA rejection, future uncertain
The bad news just keeps coming for Thousand Oaks-based Atara Biotherapeutics. Nearly a year after the biotechnology company laid off 50% of its workforce after one rejection from the U.S. Food and Drug Administration, Atara received another one on Jan. 12. In this notice, Atara, a company specializing in developing transformative therapies for patients with Read More →
Teledyne shares pop 10% after strong year-end earnings
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Ventura Land Trust acquires 101 acres at Crooked Palm in Ventura
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
PureSpectrum secures deal with PE firm
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Teledyne acquires UK’s DD-Scientific Holdings Limited
Thousand Oaks-based Teledyne Technologies, the tech and defense conglomerate, announced Jan. 14 the acquisition of DD-Scientific Holdings Limited and its subsidiary DD-Scientific Limited. DD-Scientific, founded in 2011 and headquartered in Fareham, United Kingdom, develops and manufactures high-performance gas sensors for critical applications in industries that demand absolute accuracy. Terms of the transaction were not disclosed. Read More →
Amgen snaps up Dark Blue for $840M
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Thousand Oaks’ 2025 highlights include biotech investments
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
